Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Antiangiogenic scheduling of lower dose cancer chemotherapy
Autore:
Gately, S; Kerbel, R;
Indirizzi:
Northwestern Univ, Sch Med, Div Hematol Oncol, Dept Med, Chicago, IL 60611USA Northwestern Univ Chicago IL USA 60611 ol, Dept Med, Chicago, IL 60611USA Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON, Canada Univ Toronto Toronto ON Canada s Coll, Hlth Sci Ctr, Toronto, ON, Canada Univ Toronto, Dept Med Biophys, Toronto, ON, Canada Univ Toronto Toronto ON Canada to, Dept Med Biophys, Toronto, ON, Canada
Titolo Testata:
CANCER JOURNAL
fascicolo: 5, volume: 7, anno: 2001,
pagine: 427 - 436
SICI:
1528-9117(200109/10)7:5<427:ASOLDC>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
CELL LUNG-CANCER; ENDOTHELIAL GROWTH-FACTOR; ADVANCED BREAST-CANCER; LOW-MOLECULAR-WEIGHT; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC ORAL ETOPOSIDE; CONTINUOUS-INFUSION PACLITAXEL; HUMAN CHORIONIC-GONADOTROPIN; EPITHELIAL OVARIAN-CANCER; ALTERNATE-DAY PREDNISONE;
Keywords:
angiogenesis; antineoplastic agents; drug dose and administration schedule; combination therapy; drug resistance; neoplasms;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
182
Recensione:
Indirizzi per estratti:
Indirizzo: Gately, S Northwestern Univ, Sch Med, Div Hematol Oncol, Dept Med, 676 N St Clair,Suite 850, Chicago, IL 60611 USA Northwestern Univ 676 N St Clair,Suite 850 Chicago IL USA 60611
Citazione:
S. Gately e R. Kerbel, "Antiangiogenic scheduling of lower dose cancer chemotherapy", CANCER J, 7(5), 2001, pp. 427-436

Abstract

Cancer chemotherapy utilized at maximum tolerated, toxic doses, rarely results in sustained total tumor eradication, with patients ultimately failinga variety of chemotherapeutic regimens. If tumors respond, the constituentcancer cells acquire resistance to chemotherapeutic agents, largely due totremendous genetic instability. Changing the target of these agents to thetumor's proliferating microvasculature, a more genetically stable cell, may provide important therapeutic advantages. Modifying the cyclic schedule and high doses of chemotherapeutic agents to a continuous, lower dose, "metronomic" regimen increases the efficacy of targeting the tumor microvasculature, and produces therapeutic activity with decreased toxicity. Preclinically, the antiangiogenic properties of continuous, lower-dose chemotherapy can be further enhanced by the concurrent administration of a selective angiogenesis Inhibitor. Because the target is not exclusively the tumor cell, this antiangiogenic combination strategy provides the opportunity to delay orpossibly avoid acquired resistance. Preclinical and clinical observations provide a basis for treating cancer as a chronic disease, using protracted,continuous dosing. Because appropriate chemotherapeutic agents and commercially available compounds that inhibit angiogenesis are readily available, it would be beneficial to initiate clinical trials to evaluate the antiangiogenic scheduling of chemotherapy expeditiously.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 03:47:19